Bona Fide Primary Merkel Cell Carcinoma of an Intraparotid Lymph Node in a HIV-Positive Patient

2009 ◽  
Vol 18 (5) ◽  
pp. 406-408 ◽  
Author(s):  
Francesco Ottaviani ◽  
Pasquale Capaccio ◽  
Federico Villani ◽  
Matteo Banderali ◽  
Giancarlo Pruneri ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Positive Patient ◽  
Hiv Positive ◽  
Merkel Cell ◽  
Bona Fide

scholarly journals Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma

2019 ◽  
Vol 15 ◽  
pp. 42-45 ◽  
Author(s):  
Annett Linge ◽  
Ricarda Rauschenberg ◽  
Sophia Blum ◽  
Petra Spornraft-Ragaller ◽  
Friedegund Meier ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Positive Patient ◽  
Hiv Positive ◽  
Merkel Cell ◽  
Successful Immunotherapy

scholarly journals Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy

2018 ◽  
Vol 11 (2) ◽  
pp. 467-475 ◽  
Author(s):  
Mohammed U. Al Homsi ◽  
Mai Mostafa ◽  
Khaled Fahim
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Stage Iv ◽  
Positive Patient ◽  
Response To Treatment ◽  
Exclusion Criterion ◽  
Hiv Positive ◽  
Cancer Type ◽  
Merkel Cell ◽  
Durable Response

Avelumab is indicated for the management of Merkel cell carcinoma, a rare and aggressive neuroendocrine skin cancer. Its regulatory approval followed the positive outcome of a Phase 2 trial on 88 patients with stage IV disease, which excluded patients with immunodeficiency due to HIV, a risk factor for this cancer type. We report a positive and sustained response to avelumab in an HIV-positive patient with stage IV Merkel cell carcinoma refractory to previous chemotherapy (cisplatin/etoposide) and radiotherapy. Five cycles of avelumab 10 mg/m2 resulted in the resolution of tumor activity visualized using PET-CT scanning in all affected lymph nodes. The only major side effect associated with avelumab was thyroiditis and mild hypothyroidism, a known adverse effect of this treatment, which was well controlled by L-thyroxine treatment. Treatment is ongoing and the positive response has been sustained during 5 further cycles of treatment up to date. This apparently durable response is consistent with the earlier clinical trial experience with avelumab, but seen here in a patient with HIV-associated immunodeficiency as a predisposing factor (an exclusion criterion from the previous trial). Further clinical trials with avelumab in a broader patient population with Merkel cell carcinoma are warranted.

scholarly journals Sustained Remission of a Primary Nodal Merkel Cell Carcinoma in an HIV-Positive Patient

Onkologie ◽  
2011 ◽  
Vol 34 (4) ◽  
pp. 190-192 ◽  
Author(s):  
Pierluigi Brugnaro ◽  
Erika Morelli ◽  
Marta Fiscon ◽  
Francesca Ebo ◽  
Giorgio Rosini ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Positive Patient ◽  
Hiv Positive ◽  
Sustained Remission ◽  
Merkel Cell

A Case of Nasal Merkel Cell Carcinoma Draining to a Buccinator Sentinel Lymph Node

2016 ◽  
Vol 41 (11) ◽  
pp. e480-e481 ◽  
Author(s):  
Mohammed S. Bermo ◽  
Alan Leung ◽  
Fatemeh Behnia
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Merkel Cell

scholarly journals Merkel cell carcinoma of lymph node with unknown primary has a significantly lower association with Merkel cell polyomavirus than its cutaneous counterpart

2014 ◽  
Vol 27 (9) ◽  
pp. 1182-1192 ◽  
Author(s):  
Zenggang Pan ◽  
Yuan-Yuan Chen ◽  
Xiaojun Wu ◽  
Vijay Trisal ◽  
Sharon P Wilczynski ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Merkel Cell Polyomavirus ◽  
Unknown Primary ◽  
Merkel Cell

scholarly journals Role of Sentinel Lymph Node Biopsy in the Management of Merkel Cell Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Eric P. Arruda ◽  
Kevin M. Higgins
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neck Region ◽  
Lymph Node Biopsy ◽  
Merkel Cell ◽  
Treatment Protocols ◽  
Node Biopsy

Merkel cell carcinoma (MCC) is a rare and typically aggressive form of skin cancer. It most commonly affects the elderly and has a predilection for the sun-exposed skin of the head and neck region. Other etiological factors include immune suppression, organ transplantation, and polyoma virus infection. MCC has a propensity to spread to regional lymphatics with a high locoregional recurrence rate. Since its discovery in 1972, treatment paradigms have shifted, with no consensus on optimal management strategies. Currently, standard of care includes surgical intervention to the primary and locoregional site with adjuvant radiotherapy for high-risk disease. In this paper, we discuss the history, pathology, and epidemiology of this rare disease with a focus on the evidentiary basis of treatment protocols. The use of sentinel lymph node biopsy as a management option will be the focus of this paper.

Sign in / Sign up

Export Citation Format

Share Document